Jazz Pharmaceuticals (JAZZ) Competitors

$223.61 -2.18 (-0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$224.30 +0.69 (+0.31%)

As of 07:06 PM Eastern

JAZZ vs. AXSM, ZTS, RPRX, CORT, and NKTR

Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Axsome Therapeutics (AXSM), Zoetis (ZTS), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), and Nektar Therapeutics (NKTR). These companies are all part of the "medical" sector.

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Jazz Pharmaceuticals presently has a consensus price target of $230.56, indicating a potential upside of 3.11%. Axsome Therapeutics has a consensus price target of $251.26, indicating a potential upside of 16.07%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Axsome Therapeutics had 12 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 40 mentions for Axsome Therapeutics and 28 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.63 beat Axsome Therapeutics' score of 0.23 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	5 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	13 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Jazz Pharmaceuticals has a net margin of 0.66% compared to Axsome Therapeutics' net margin of -26.59%. Jazz Pharmaceuticals' return on equity of 14.56% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Jazz Pharmaceuticals has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Axsome Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.29	-$356.15M	-$0.02	N/A
Axsome Therapeutics	$708.24M	15.73	-$183.17M	-$3.73	N/A

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Zoetis?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Zoetis has a net margin of 27.80% compared to Jazz Pharmaceuticals' net margin of 0.66%. Zoetis' return on equity of 66.85% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Zoetis	27.80%	66.85%	18.79%

Zoetis has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.29	-$356.15M	-$0.02	N/A
Zoetis	$9.53B	3.38	$2.67B	$6.03	12.71

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Jazz Pharmaceuticals has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

In the previous week, Zoetis had 21 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 49 mentions for Zoetis and 28 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.63 beat Zoetis' score of 0.36 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	5 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	23 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	8 Negative mention(s)	4 Very Negative mention(s)	Neutral

Jazz Pharmaceuticals currently has a consensus price target of $230.56, indicating a potential upside of 3.11%. Zoetis has a consensus price target of $141.25, indicating a potential upside of 84.35%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Zoetis	1 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Zoetis beats Jazz Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Royalty Pharma has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.44B	12.21	$770.95M	$1.47	35.14
Jazz Pharmaceuticals	$4.27B	3.29	-$356.15M	-$0.02	N/A

Royalty Pharma presently has a consensus target price of $53.71, indicating a potential upside of 4.00%. Jazz Pharmaceuticals has a consensus target price of $230.56, indicating a potential upside of 3.11%. Given Royalty Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Royalty Pharma is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Royalty Pharma and Royalty Pharma both had 28 articles in the media. Royalty Pharma's average media sentiment score of 0.71 beat Jazz Pharmaceuticals' score of 0.63 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	8 Very Positive mention(s)	3 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	5 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by company insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Royalty Pharma has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Royalty Pharma has a net margin of 33.88% compared to Jazz Pharmaceuticals' net margin of 0.66%. Royalty Pharma's return on equity of 29.25% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jazz Pharmaceuticals presently has a consensus target price of $230.56, suggesting a potential upside of 3.11%. Corcept Therapeutics has a consensus target price of $74.67, suggesting a potential upside of 45.83%. Given Corcept Therapeutics' higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Corcept Therapeutics	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

Jazz Pharmaceuticals has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

Corcept Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.29	-$356.15M	-$0.02	N/A
Corcept Therapeutics	$769.10M	7.15	$99.65M	$0.35	146.29

In the previous week, Jazz Pharmaceuticals and Jazz Pharmaceuticals both had 28 articles in the media. Corcept Therapeutics' average media sentiment score of 1.00 beat Jazz Pharmaceuticals' score of 0.63 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	5 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics has a net margin of 6.14% compared to Jazz Pharmaceuticals' net margin of 0.66%. Jazz Pharmaceuticals' return on equity of 14.56% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Corcept Therapeutics	6.14%	7.40%	5.76%

Summary

Corcept Therapeutics beats Jazz Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

In the previous week, Jazz Pharmaceuticals had 5 more articles in the media than Nektar Therapeutics. MarketBeat recorded 28 mentions for Jazz Pharmaceuticals and 23 mentions for Nektar Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.63 beat Nektar Therapeutics' score of 0.01 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	14 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Jazz Pharmaceuticals	5 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nektar Therapeutics currently has a consensus target price of $149.63, indicating a potential upside of 90.07%. Jazz Pharmaceuticals has a consensus target price of $230.56, indicating a potential upside of 3.11%. Given Nektar Therapeutics' higher probable upside, equities analysts clearly believe Nektar Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Nektar Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	48.09	-$164.08M	-$8.42	N/A
Jazz Pharmaceuticals	$4.27B	3.29	-$356.15M	-$0.02	N/A

75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Jazz Pharmaceuticals has a net margin of 0.66% compared to Nektar Therapeutics' net margin of -284.18%. Jazz Pharmaceuticals' return on equity of 14.56% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-308.94%	-58.99%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

Nektar Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Summary

Jazz Pharmaceuticals beats Nektar Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Jazz Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JAZZ vs. The Competition

Export

Metric	Jazz Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.03B	$3.37B	$6.18B	$12.27B
Dividend Yield	N/A	2.24%	2.78%	5.22%
P/E Ratio	-11,174.91	15.19	20.66	25.70
Price / Sales	3.29	193.51	529.27	64.55
Price / Cash	13.88	56.93	27.81	36.27
Price / Book	3.15	6.94	9.77	6.74
Net Income	-$356.15M	$24.11M	$3.54B	$333.09M
7 Day Performance	N/A	N/A	N/A	0.52%
1 Month Performance	15.14%	4.62%	6.28%	8.98%
1 Year Performance	128.62%	78.21%	41.80%	42.44%

Jazz Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JAZZ Jazz Pharmaceuticals	3.4806 of 5 stars	$223.61 -1.0%	$230.56 +3.1%	+130.8%	$14.03B	$4.27B	N/A	2,890	Earnings Report
AXSM Axsome Therapeutics	3.1175 of 5 stars	$224.03 +8.5%	$235.79 +5.2%	+101.7%	$10.62B	$638.50M	N/A	380	Earnings Report High Trading Volume
ZTS Zoetis	4.8543 of 5 stars	$112.81 -1.2%	$151.75 +34.5%	-48.2%	$48.02B	$9.47B	18.74	14,500	Earnings Report Analyst Forecast
RPRX Royalty Pharma	4.0975 of 5 stars	$50.20 +1.5%	$50.33 +0.3%	+53.2%	$28.54B	$2.38B	37.19	80	Earnings Report Analyst Upgrade
CORT Corcept Therapeutics	4.2703 of 5 stars	$51.60 +0.4%	$74.67 +44.7%	-25.6%	$5.52B	$761.41M	147.43	300	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JAZZ) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, ZTS, RPRX, CORT, and NKTR

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Zoetis?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Summary

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Nektar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, ZTS, RPRX, CORT, and NKTR

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Do analysts rate JAZZ or AXSM?

Does the media refer more to JAZZ or AXSM?

Do institutionals & insiders believe in JAZZ or AXSM?

Is JAZZ or AXSM more profitable?

Which has more risk & volatility, JAZZ or AXSM?

Which has preferable earnings & valuation, JAZZ or AXSM?

Summary

How does Jazz Pharmaceuticals compare to Zoetis?

Is JAZZ or ZTS more profitable?

Which has higher valuation & earnings, JAZZ or ZTS?

Do insiders and institutionals believe in JAZZ or ZTS?

Which has more risk & volatility, JAZZ or ZTS?

Does the media prefer JAZZ or ZTS?

Do analysts prefer JAZZ or ZTS?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Which has preferable earnings and valuation, RPRX or JAZZ?

Do analysts prefer RPRX or JAZZ?

Does the media favor RPRX or JAZZ?

Do insiders & institutionals have more ownership in RPRX or JAZZ?

Which has more risk and volatility, RPRX or JAZZ?

Is RPRX or JAZZ more profitable?

Summary

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Do institutionals & insiders hold more shares of JAZZ or CORT?

Do analysts recommend JAZZ or CORT?

Which has more risk & volatility, JAZZ or CORT?

Which has preferable earnings and valuation, JAZZ or CORT?

Does the media favor JAZZ or CORT?

Is JAZZ or CORT more profitable?

Summary

How does Jazz Pharmaceuticals compare to Nektar Therapeutics?

Does the media refer more to NKTR or JAZZ?

Do analysts recommend NKTR or JAZZ?

Which has stronger earnings & valuation, NKTR or JAZZ?

Do insiders and institutionals believe in NKTR or JAZZ?

Is NKTR or JAZZ more profitable?

Which has more volatility and risk, NKTR or JAZZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools